Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. Evixapodlin has anticancer and antiviral functions.
Evixapodlin (compound 139) enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8 T Cells and CD4 T Cells. Evixapodlin also enhances the frequency of GrB cells among HBV-specific CD8 and CD4 T cells. The ability of Evixapodlin to enhance the antiviral functions of HBV-specific CD8 and CD4 T cells in vitro is comparable to those of Durvalumab.
体内研究
Evixapodlin (Compound 139; 10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment shows >90% PD-L1 target occupancy (TO) on the tumor cells. Evixapodlin significantly inhibits tumor growth in a human PD-L1 expressing MC38 mouse colorectal tumor model.
Animal Model:
Female C57BL/6 mice injected with MC38 tumor cells
Dosage:
10 mg/kg, 25 mg/kg, and 50 mg/kg
Administration:
Intraperitoneal injection, daily, for 6 days
Result:
Showed greater than 90% TO on the tumors and inhibited tumor growth in vivo.
分子式
C34H36Cl2N8O4
分子量
691.61
CAS号
2374856-75-2
运输条件
Room temperature in continental US; may vary elsewhere.